(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol;1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 吡咯并嘧啶核苷和核苷酸
• 英文名称: (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol;1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea
• 化学式: C19H29N7O11
• 分子量: 531.5
• InChiKey: ZICKISBTPRMIEZ-ISMCLEJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.27
• 重原子数：
  37
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  279
• 氢给体数：
  9
• 氢受体数：
  15

文献信息

• Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
  申请人：Genelux Corporation

  公开号：EP2202297B1

  公开（公告）日：2014-05-14
• [EN] ILT3-BINDING AGENTS AND METHODS OF USE THEREOF<br/>[FR] AGENTS DE LIAISON À ILT3 ET LEURS MÉTHODES D'UTILISATION
  申请人：[en]NGM BIOPHARMACEUTICALS, INC.

  公开号：WO2021127200A1

  公开（公告）日：2021-06-24

  The present disclosure provides binding agents, such as antibodies, that specifically bind ILT3, including human ILT3, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.